GENEVA, Switzerland 20 June 2017 – Last week Clarivate Analytics released the 2017 Impact Factor (IF) in the Journal Citation Reports©. The Journal of Hepatology achieved exceptional results with a 2016 IF score of 12.486, up from the 2015 score of 10.590. The Journal of Hepatology was cited 33,566 in 2016, making it the fifth most highly cited journal in the field of Gastroenterology and Hepatology.
The ranking also reveals that the Journal of Hepatology continues to surge ahead with an impressive 17% increase in one year. To date, the 2016 score is the highest the Journal of Hepatology achieved, surpassing the 2014 IF score of 11.336.
"This increase in the impact factor by 17% up to 12.486 is unprecedented and I gratefully acknowledge the huge contribution of the authors who decide to publish their best papers in the Journal, the efforts of the whole Editorial team, the office in Geneva and the EASL Governing Board in getting us to this point," said Prof Rajiv Jalan, Editor-in-Chief of the Journal of Hepatology.
The record high score reaffirms the continued commitment of EASL, The Home of Hepatology, to provide the scientific community with a high-quality publication that delivers impactful content as the Home of Liver Research.
"The EASL Governing Board congratulates the Editorial team on the great success of the highest impact factor ever for the Journal of Hepatology. The Journal of Hepatology is an EASL flagship, and thanks to the hard work of Rajiv Jalan, as well as all the previous Editors-in-chief, the journal of our society has now found itself a stable position in the top tier of academic publishing," said Prof Tom Hemming-Karlsen, Secretary General of EASL.
An impact factor is a measure of a journal's significance in an academic field. It considers the frequency with which the average article in a journal is cited in a given year. This data helps indicate a journal's relative importance when compared to other publications in the same field. The Journal of Hepatology publishes 12 issues a year and covers a wide variety of topics in clinical and basic research within the field.
About the Journal of Hepatology
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. www.journal-of-hepatology.eu
About EASL – The Home of Hepatology
In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. www.easl.eu
Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.
PRESS RELEASE FROM EASL
Contact: Hyatt Antognini-Amin
PR & Media Coordinator, EASL
New study evaluates efficacy of PET imaging to manage chronic liver diseases
EASL governing board announces new Vice-Secretary
A web-based program is as effective as group counseling for patients with non-alcoholic fatty liver disease